E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 6/25/2012 in the Prospect News PIPE Daily.

Rosetta Genomics intends to price public offering of ordinary stock

Offering conducted to fund operations and general corporate purposes

By Devika Patel

Knoxville, Tenn., June 25 - Rosetta Genomics Ltd. will price a public offering of ordinary stock, according to a Form F-1 filed Monday with the Securities and Exchange Commission. The deal has a 45-day greenshoe.

Aegis Capital Corp. is the underwriter.

Proceeds will be used for operations and other general corporate purposes.

Based in Rehovot, Israel, Rosetta Genomics develops and provides microRNA-based molecular diagnostics.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.